CPT code 87625 designates a laboratory nucleic acid test that detects high-risk human papillomavirus genotypes, specifically types 16 and 18, with type 45 when performed. This genotype-specific molecular assay supports identification of HPV strains most strongly associated with cervical and other anogenital cancers, informing clinical management and public health surveillance. Nationally, HPV genotype testing is a component of cervical cancer screening algorithms and has implications for diagnostic workflows and laboratory reimbursement.

Key payers in the coverage landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of typical coverage considerations, payer policies, and billing practices related to molecular HPV testing. The publication summarizes clinical context for genotype-specific HPV testing, common service settings (laboratory and hospital laboratories), and payer applicability across major commercial and federal insurers. It also outlines the benchmarks and policy updates relevant to molecular diagnostic billing for HPV where available, and highlights operational considerations for laboratories submitting claims for CPT code 87625.

Data not available in the input is noted where applicable.